Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$13.61
▲ $0.08 (+0.6%)
Market data updated: 09/20 03:57 PM
News analyzed: 09/20/2026
Market Cap
$533.05M
Day Range
$13.14 - $13.63
52-Week Range
$7.14 - $17.40
Beta
—
Next Earnings
09.11.2026
Support
$13.13
Resistance
$17.40
BWAY is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+70.6% (1Y)
⚠️ Insufficient data for a reliable StockIQ Score
Only 3 of 7 categories available — Fundamental, Growth, Valuation, Quality unavailable.
Strengths: 2/13 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Calmar Ratio (return vs. drawdown)
Calmar: 2.33 (3y annualized return 84.8% / max drawdown 36.3%)
Risk
Biggest negative driver
Daily volatility (ATR)
ATR: 4.3% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
49
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
29
Risk
50
Sentiment
100
Fundamental
No data available
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **BrainsWay Ltd.** has centered on its **clinical advancements in deep transcranial magnetic stimulation (Deep TMS™)**, particularly promising pilot study results showing **reduced suicidal ideation (70% drop) in depression patients** and **improved outcomes in those with comorbid early-stage Alzheimer’s**. Analysts have repeatedly **upgraded its stock rating** (e.g., Buy from HC Wainwright, Ladenburg Thalmann) and **raised price targets**, projecting significant upside (up to 30%). While revenue growth (35% YoY) and margin gains were noted, some reports also highlighted **market saturation and competition risks**. The focus remains on its **neuromodulation technology’s potential** in mental health and neurodegenerative conditions.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about BrainsWay Ltd.. News trend score: 100. Reason: 13 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
18
🎯 Conviction (vs. Emotion)
50
Psychology
29
Fundamentals
—
Technical
29
Valuation
—
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-9%
Market Narrative
59
Fundamental Reality
50
Narrative Gap
+9
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s dominant anchoring behavior suggests traders are fixating on the 1.0% support level, likely due to its proximity. The near-perfect news sentiment (100/100) contrasts with weak momentum and neutral technical indicators, indicating potential misalignment between narrative and reality. The absence of panic or herding implies confidence in the anchor’s validity, though the narrative gap (8 points) hints at overestimation of positive developments. The key question: will traders hold firm at support, or will the gap between optimism and technical reality widen?
Updated: 09/09/2026, 01:59 PM
What could change this?
👥 What the crowd believes
"HC Wainwright & Co. analyst raises BrainsWay price target from $17 to $19."
"BrainsWay reports 70% reduction in patients experiencing suicidal ideation in Deep TMS™ study."
"Brainsway upgraded to Buy by Zacks analysts."
"BrainsWay reports 35% YoY revenue growth but valuation looks rich."
📈 12D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 88/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
The methodologies here split sharply between bullish and bearish signals for BWAY, reflecting starkly different analytical lenses. Samuel Armstrong Nelson’s high score (89) suggests the stock is oversold and cyclically positioned for a rebound, while Howard Marks (both cycle and general) leans neutral to cautious, noting mixed fundamentals and potentially elevated expectations. Meanwhile, the lack of decisive data for Graham, Fisher, or Lynch—all scoring 50—implies a fundamental uncertainty, though their frameworks would typically demand more concrete evidence before committing. On the other end, the lowest scores (from Housel, Livermore, and Veblen) flag volatility, trend resistance, and speculative growth motives, respectively, painting a picture of risk or overvaluation. The contrast underscores how technical cyclists (like Nelson) and contrarian value investors (like Marks) might see opportunity where behavioral or trend-following strategists (like Livermore or Housel) see red flags.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 88
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 72
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 54
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Jack Schwager
Market Wizards (1989)
🟡 48
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 47
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 36
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 33
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 29
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 20
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 282 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 7 bearish · 3 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 13 positive, 5 neutral, 2 negative out of the last 20 articles.
Yahoo · 11.9.2026
Insider Monkey · 11.9.2026
Benzinga · 10.9.2026
Yahoo · 9.9.2026
Zacks · 9.9.2026
Benzinga · 8.9.2026
Yahoo · 8.9.2026
GlobeNewswire · 8.9.2026
Benzinga · 31.8.2026
Benzinga · 31.8.2026
Zacks · 27.8.2026
GlobeNewswire · 27.8.2026
Zacks · 17.8.2026
Zacks · 17.8.2026
SeekingAlpha · 13.8.2026
Benzinga · 13.8.2026
MarketBeat · 13.8.2026
GuruFocus.com · 12.8.2026
SeekingAlpha · 12.8.2026
Benzinga · 12.8.2026
StockIQ doesn't currently have enough real data to compute a reliable score for BrainsWay Ltd. (BWAY) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for BWAY specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
BWAY's technical score is 29/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Calmar: 2.33 (3y annualized return 84.8% / max drawdown 36.3%); Price is above the 200-day average.
Based on the real signals StockIQ computed: ATR: 4.3% of price; Price is below the 50-day average; MACD histogram is negative — falling momentum.
StockIQ has no recorded dividend payment history for BWAY.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 14 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Moiseyev Gilad | Open Market Sale | 15.6.2026 | 5,000 | -5,000 | — |
| Moiseyev Gilad | Open Market Sale | 15.6.2026 | 53,098 | -5,000 | — |
| Roth Yiftach | Open Market Sale | 2.6.2026 | 1,000 | -1,000 | — |
| Roth Yiftach | Open Market Sale | 2.6.2026 | 2,000 | -2,000 | — |
| Roth Yiftach | Open Market Sale | 2.6.2026 | 1,074,305 | -1,000 | — |
| Roth Yiftach | Open Market Sale | 2.6.2026 | 1,072,305 | -2,000 | — |
| Roth Yiftach | Open Market Sale | 1.6.2026 | 2,000 | -2,000 | — |
| Roth Yiftach | Open Market Sale | 1.6.2026 | 2,000 | -2,000 | — |
| Roth Yiftach | Open Market Sale | 1.6.2026 | 1,077,305 | -2,000 | — |
| Roth Yiftach | Open Market Sale | 1.6.2026 | 1,075,305 | -2,000 | — |
| Mitrany Rayten Michal Ety | Open Market Sale | 26.5.2026 | 7,980 | -7,980 | — |
| Mitrany Rayten Michal Ety | Open Market Sale | 26.5.2026 | 12,500 | -7,980 | — |
| Moiseyev Gilad | Exercise of Derivative Securities | 25.5.2026 | 7,500 | -7,500 | — |
| Mitrany Rayten Michal Ety | Open Market Sale | 25.5.2026 | 10,000 | -10,000 | — |
| Moiseyev Gilad | Exercise of Derivative Securities | 25.5.2026 | 7,500 | +7,500 | — |
| Moiseyev Gilad | Tax Withholding in Shares | 25.5.2026 | 1,902 | -1,902 | — |
| Mitrany Rayten Michal Ety | Open Market Sale | 25.5.2026 | 20,480 | -10,000 | — |
| Moiseyev Gilad | Exercise of Derivative Securities | 25.5.2026 | 60,000 | +7,500 | — |
| Moiseyev Gilad | Tax Withholding in Shares | 25.5.2026 | 58,098 | -1,902 | — |
| Moiseyev Gilad | Exercise of Derivative Securities | 25.5.2026 | 22,500 | -7,500 | — |
| Mitrany Rayten Michal Ety | Exercise of Derivative Securities | 20.5.2026 | 17,500 | -17,500 | — |
| Mitrany Rayten Michal Ety | Tax Withholding in Shares | 20.5.2026 | 6,080 | -6,080 | — |
| Mitrany Rayten Michal Ety | Exercise of Derivative Securities | 20.5.2026 | 17,500 | +17,500 | — |
| Mitrany Rayten Michal Ety | Exercise of Derivative Securities | 20.5.2026 | 36,560 | +17,500 | — |
| Mitrany Rayten Michal Ety | Tax Withholding in Shares | 20.5.2026 | 30,480 | -6,080 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
208,111 shares short as of 2026-08-31 · vs. 116,515 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
54.5% of trading volume this week was short selling, vs. 58.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology